We would like to extend our sincere thanks to all customers and interested visitors for the engaging conversations and valuable exchange during CACLP 2025, held from March 22 to 24. It was a pleasure to reconnect with familiar faces and to welcome new contacts at our booth.

Throughout the event, we had numerous promising discussions, with a strong focus on regulatory approvals for Europe and the WHO. Key topics included HIV, HBV, syphilis, HPV, HTLV, dengue fever, and malaria – reflecting the global relevance of our work in clinical diagnostics.

A special highlight this year was the presence of our study team under their new name: IVD TRIALS GmbH. As an independent company, IVD TRIALS brings even more flexibility and a sharpened focus to clinical IVD studies – and CACLP 2025 marked their successful debut under this new identity.

We’re already looking forward to continuing these discussions and welcoming you again at CACLP 2026!

And for those who couldn’t attend in person – we’ve got you covered. Our NeckarBiotechnology office in Shanghai is always here to support our customers in China.